ArticleRedox biology2026
Oxidative stress-driven m
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy is the standard first-line treatment for advanced lung adenocarcinoma (LUAD). However, cisplatin resistance often leads to therapeutic failure, which subsequently results in cancer recurrence and metastasis. Here, we identify NSUN5 as a key driver of cisplatin resistance in response to oxidative stress. Cisplatin-induced reactive oxygen species (ROS) not only elevate NSUN5 expression through Nrf2-dependent transcriptional activation, but also enhance its methyltransferase activity by potentiating Cys359 for RNA capture. NSUN5 overexpression is clinically correlated with cisplatin resistance and poor prognosis in LUAD. Mechanistically, integrated RNA bisulfite sequencing (Bis-seq) and RNA sequencing (RNA-seq) analyses identified GLUT1 as a key target. NSUN5 catalyzes m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.